厄贝沙坦氢氯噻嗪片治疗原发性高血压临床效果观察  

Clinical effect observation of Irbesartan and hydrochlorothiazide tablets in treatment of essential hypertension

作　　者：林海云[1] 陈以初[1] 熊斌[1] 

机构地区：[1]广东医学院附属厚街医院心内科,广东东莞523000

出　　处：《中国当代医药》2013年第17期101-102,共2页China Modern Medicine

摘　　要：目的探讨厄贝沙坦氢氯噻嗪片对原发性高血压的临床疗效。方法选择本院收治的原发性高血压128例患者作为研究对象,随机分为观察组和对照组,每组各64例,对照组给予厄贝沙坦片治疗,观察组给予厄贝沙坦氢氯噻嗪片治疗,两组治疗时间均为4周。观察两组治疗前后血压变化及不良反应的发生率。结果治疗4周后,观察组收缩压和舒张压均显著低于对照组,差异有统计学意义(P<0.05);观察组总有效率分别为89.1%,对照组总有效率为79.7%,两组比较差异有统计学意义(P<0.05)。两组均未见严重不良反应发生。结论厄贝沙坦氢氯噻嗪片治疗原发性高血压疗效显著,且不良反应少,安全性较好,值得临床推广使用。Objective To explore clinical efficacy of Irbesartan and hydroehlorothiazide tablets in the treatment of es- sential hypertension. Methods One hundred and twenty-eight cases with essential hypertension in our hospital were randomly divided into observation group and control group, each group had 64 cases, the control group were treated Irbesartan tablets, and the observation group were treated Irbesartan and hydrochlorothiazide tablets. The treatment courses of two groups were 4 weeks. Results After 4 weeks of treatment, the observation group systolic blood pressure and diastolic blood pressure was significantly lower than that of the control group, the difference was statistically sig- nificant （P 〈 0.05）; The total effective rate was 89.1% in observation group and 79.7% in control group, the difference was statistically significant （P 〈 0.05）. Both groups had no serious adverse reactions. Conclusion Irbesartan and Hy- droehlorothiazide tablets in the treatment of essential hypertension has significant effect, and its adverse reactions are fewer and of good safety, is worthy of clinical use.

关 键 词：厄贝沙坦氢氯噻嗪片 原发性高血压 临床观察 

分 类 号：R972.4[医药卫生—药品]